Literature DB >> 24801505

NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.

Magdalena M Grabowska1, Amicia D Elliott, David J DeGraff, Philip D Anderson, Govindaraj Anumanthan, Hironobu Yamashita, Qian Sun, David B Friedman, David L Hachey, Xiuping Yu, Jonathan H Sheehan, Jung-Mo Ahn, Ganesh V Raj, David W Piston, Richard M Gronostajski, Robert J Matusik.   

Abstract

Androgen receptor (AR) action throughout prostate development and in maintenance of the prostatic epithelium is partly controlled by interactions between AR and forkhead box (FOX) transcription factors, particularly FOXA1. We sought to identity additional FOXA1 binding partners that may mediate prostate-specific gene expression. Here we identify the nuclear factor I (NFI) family of transcription factors as novel FOXA1 binding proteins. All four family members (NFIA, NFIB, NFIC, and NFIX) can interact with FOXA1, and knockdown studies in androgen-dependent LNCaP cells determined that modulating expression of NFI family members results in changes in AR target gene expression. This effect is probably mediated by binding of NFI family members to AR target gene promoters, because chromatin immunoprecipitation (ChIP) studies found that NFIB bound to the prostate-specific antigen enhancer. Förster resonance energy transfer studies revealed that FOXA1 is capable of bringing AR and NFIX into proximity, indicating that FOXA1 facilitates the AR and NFI interaction by bridging the complex. To determine the extent to which NFI family members regulate AR/FOXA1 target genes, motif analysis of publicly available data for ChIP followed by sequencing was undertaken. This analysis revealed that 34.4% of peaks bound by AR and FOXA1 contain NFI binding sites. Validation of 8 of these peaks by ChIP revealed that NFI family members can bind 6 of these predicted genomic elements, and 4 of the 8 associated genes undergo gene expression changes as a result of individual NFI knockdown. These observations suggest that NFI regulation of FOXA1/AR action is a frequent event, with individual family members playing distinct roles in AR target gene expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24801505      PMCID: PMC4042066          DOI: 10.1210/me.2013-1213

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  76 in total

1.  Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding.

Authors:  Simon C Biddie; Sam John; Pete J Sabo; Robert E Thurman; Thomas A Johnson; R Louis Schiltz; Tina B Miranda; Myong-Hee Sung; Saskia Trump; Stafford L Lightman; Charles Vinson; John A Stamatoyannopoulos; Gordon L Hager
Journal:  Mol Cell       Date:  2011-07-08       Impact factor: 17.970

2.  Involvement of Matrin 3 and SFPQ/NONO in the DNA damage response.

Authors:  Maayan Salton; Yaniv Lerenthal; Shih-Ya Wang; David J Chen; Yosef Shiloh
Journal:  Cell Cycle       Date:  2010-04-15       Impact factor: 4.534

3.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

5.  FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.

Authors:  Biswajyoti Sahu; Marko Laakso; Päivi Pihlajamaa; Kristian Ovaska; Ievgenii Sinielnikov; Sampsa Hautaniemi; Olli A Jänne
Journal:  Cancer Res       Date:  2012-12-26       Impact factor: 12.701

6.  The sequence read archive.

Authors:  Rasko Leinonen; Hideaki Sugawara; Martin Shumway
Journal:  Nucleic Acids Res       Date:  2010-11-09       Impact factor: 16.971

7.  Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

Authors:  David J DeGraff; Peter E Clark; Justin M Cates; Hironobu Yamashita; Victoria L Robinson; Xiuping Yu; Mark E Smolkin; Sam S Chang; Michael S Cookson; Mary K Herrick; Shahrokh F Shariat; Gary D Steinberg; Henry F Frierson; Xue-Ru Wu; Dan Theodorescu; Robert J Matusik
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

8.  The mutational landscape of lethal castration-resistant prostate cancer.

Authors:  Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins
Journal:  Nature       Date:  2012-07-12       Impact factor: 49.962

9.  The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.

Authors:  Naomi L Sharma; Charlie E Massie; Antonio Ramos-Montoya; Vincent Zecchini; Helen E Scott; Alastair D Lamb; Stewart MacArthur; Rory Stark; Anne Y Warren; Ian G Mills; David E Neal
Journal:  Cancer Cell       Date:  2012-12-20       Impact factor: 31.743

10.  Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA.

Authors:  Dong Wang; Ivan Garcia-Bassets; Chris Benner; Wenbo Li; Xue Su; Yiming Zhou; Jinsong Qiu; Wen Liu; Minna U Kaikkonen; Kenneth A Ohgi; Christopher K Glass; Michael G Rosenfeld; Xiang-Dong Fu
Journal:  Nature       Date:  2011-05-15       Impact factor: 49.962

View more
  43 in total

1.  Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.

Authors:  Opal L Reddy; Justin M Cates; Lan L Gellert; Henry S Crist; Zhaohai Yang; Hironobu Yamashita; John A Taylor; Joseph A Smith; Sam S Chang; Michael S Cookson; Chaochen You; Daniel A Barocas; Magdalena M Grabowska; Fei Ye; Xue-Ru Wu; Yajun Yi; Robert J Matusik; Klaus H Kaestner; Peter E Clark; David J DeGraff
Journal:  Am J Pathol       Date:  2015-05       Impact factor: 4.307

2.  Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1.

Authors:  Leiming Wang; Mafei Xu; Chung-Yang Kao; Sophia Y Tsai; Ming-Jer Tsai
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.

Authors:  Thomas M Campbell; Mauro A A Castro; Kelin Gonçalves de Oliveira; Bruce A J Ponder; Kerstin B Meyer
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

Review 4.  Prostate organogenesis: tissue induction, hormonal regulation and cell type specification.

Authors:  Roxanne Toivanen; Michael M Shen
Journal:  Development       Date:  2017-04-15       Impact factor: 6.868

5.  Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells.

Authors:  Ekaterina A Potter; Evgenia V Dolgova; Anastasia S Proskurina; Yaroslav R Efremov; Alexandra M Minkevich; Aleksey S Rozanov; Sergey E Peltek; Valeriy P Nikolin; Nelly A Popova; Igor A Seledtsov; Vladimir V Molodtsov; Evgeniy L Zavyalov; Oleg S Taranov; Sergey I Baiborodin; Alexander A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2017-02-07

6.  Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation.

Authors:  Cody A Siciliano; Kaustuv Saha; Erin S Calipari; Steve C Fordahl; Rong Chen; Habibeh Khoshbouei; Sara R Jones
Journal:  J Neurosci       Date:  2017-11-24       Impact factor: 6.167

7.  Differential impact of RB status on E2F1 reprogramming in human cancer.

Authors:  Christopher McNair; Kexin Xu; Amy C Mandigo; Matteo Benelli; Benjamin Leiby; Daniel Rodrigues; Johan Lindberg; Henrik Gronberg; Mateus Crespo; Bram De Laere; Luc Dirix; Tapio Visakorpi; Fugen Li; Felix Y Feng; Johann de Bono; Francesca Demichelis; Mark A Rubin; Myles Brown; Karen E Knudsen
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

8.  Discovery and validation of information theory-based transcription factor and cofactor binding site motifs.

Authors:  Ruipeng Lu; Eliseos J Mucaki; Peter K Rogan
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

9.  Enhancing brown fat with NFIA.

Authors:  Suzanne N Shapira; Patrick Seale
Journal:  Nat Cell Biol       Date:  2017-08-31       Impact factor: 28.824

10.  Benzyl isothiocyanate inhibits breast cancer cell tumorigenesis via repression of the FoxH1-Mediated Wnt/β-catenin pathway.

Authors:  Yantao Liu; Lingli Zhang; Yao Meng; Liang Huang
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.